Notably, the beneficial effects of KAT II inhibitors may be further enhanced by A2AR agonists and may also improve negative symptoms in schizophrenia patients via allosteric inhibition of D2R signaling in A2AR-D2R heteroreceptor complexes of ventral striatal-pallidal GABA neurons (Borroto-Escuela et al., 2020). This evidence concerns the gene ADORA2A and schizophrenia.